H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Rapport Therapeutics (RAPP) to $40 from $34 and keeps a Buy rating on the shares. The firm says the new data support RAP-219’s potential to become a “major player in the fast-expanding” focal onset seizures market. RAP-219 showed “rapid and deep” anti-seizure effect across disease severities in refractory focal epilepsy patients in the Phase 2 data, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Promising Outlook for Rapport Therapeutics: Buy Rating Backed by RAP-219’s Clinical Success and Strategic Growth Plans
- Rapport Therapeutics announces new data, post hox analysis on RAP-219
- Buy Rating for Rapport Therapeutics: Promising Efficacy and Market Potential of RAP-219 in Epilepsy and Bipolar Mania
- Rapport Therapeutics initiated with a Buy at BTIG
- Buy Rating for Rapport Therapeutics: Promising RAP-219 Results and Strong Financial Position